Emerging Companies

The U.S. bioscience industry continued to score employment gains through 2008 - the first year of the recent economic downturn, according to a study released today by Battelle and the Biotechnology Industry Organization (BIO).

Biotechnology is all around us and is already a big part of our lives, providing breakthrough products and technologies to combat disease, reduce our environmental footprint, feed the hungry, and make useful products.

The “Valley of Death” — that sketchy period between when a startup settles on a technical approach and delivers a product to market — needn’t crush an early-stage biofuels business, say officers at three companies that are making that journey now.

There may be no summer lovin’ for biotechs. By most accounts, investors will remain tightfisted with their cash for some time, opening up their wallets for only the most promising investments. In a sign of how devastating the global economic crisis has become for the industry, more than a third of the 344 public biotechs had less than six months cash on hand by the end of March 2009, according to Burrill & Company statistics. And the situation is probably even bleaker among smaller, private companies.

The study provides first-of-its-kind data on the importance of university/industry research and development partnerships to the U.S. economy.

The health reform debate is heating up and, in at least one respect, slowing down a bit.

Tracy Krughoff speaks with Fernando Quesada, executive director of the Biotechnology Center of Excellence Corporation, who is organizing Mexico’s participation in the BIO International Convention.

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

Letters, Testimony & Comments

July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals On behalf of the Biotechnology Industry...
March 16 2012
Dear Majority Leader Reid and Minority Leader McConnell: On behalf of the Biotechnology Industry Organization (BIO) and its more than 1...
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer OncoMed Pharmaceuticals highlights the importance of capital...
December 1 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of...
May 25 2011
Good morning Chairman Casey, Vice Chairman Brady, Ranking Member DeMint, Ranking Member Hinchey, Members of the Committee, ladies, and...

Press Releases

January 8 2013
WASHINGTON DC, January 8, 2013 -- BIO lauds the Administration and the U.S. Small Business Association (SBA) for...
September 25 2012
Washington, D.C. (September 25, 2012) – The Biotechnology Industry Organization (BIO) applauds Sens. Robert...
July 26 2012
Washington, D.C. (July 26, 2012) – Today, the House Subcommittee on Capital Markets held a hearing entitled...
July 20 2012
Washington, D.C. (July 20, 2012) – Today, Representative Michael Fitzpatrick (R-PA) introduced H.R. 6161, the...
June 6 2012
Washington, DC and New York, NY, Wednesday, June 6, 2012 -The 4th Annual Scientific American Worldview Report and...